Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.

Funding agencies:DMW: personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Merck Sharpe and Dohme, Novartis, Roche, Sanofi, Bayer, Janssen-Cilag, Lilly, NovoNordisk; non-financial support from Sanofi Germany, outside the submitted work. GA, RC, JD, EF, HG, AGO, WFR, ES: none. AVE: personal fees from Amgen Switzerland, Astra Zeneca Switzerland, Merck Sharpe and Dohme Switzerland, Sanofi Aventis, outside the submitted work; and member of the Executive Board of the European Atherosclerosis Society as well as the president of the Swiss Working Group on Lipids and Atherosclerosis (= Swiss Atherosclerosis Society), which both published own recommendations for the prevention of heart disease by lipid-lowering therapy.
Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

Assmann, GerdAssmann-Foundation for Prevention, Münster, Germany (författare)
Carmena, RafaelUniversity, Valencia, Spain (författare)
Davignon, JeanFaculty of Medicine at the Université de Montréal, Canada (författare)
von Eckardstein, ArnoldUniversity Hospital of Zurich, Switzerland (författare)
Farinaro, EduardoMedical School University of Naples Federico II, Italy (författare)
Greten, HeinerAsklepios Clinic St Georg, Hamburg, Germany (författare)
Olsson, Anders GLinköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Endokrinmedicinska kliniken,Stockholm Heart Centre, Sweden(Swepub:liu)andol21 (författare)
Riesen, Walter FInstitute for Laboratory Medicine, St Gallen, Switzerland (författare)
Shlyakhto, EvgenyiRussian Federation Agency of Health and Social Development, Saint Petersburg, Russia (författare)
Asklepios Clinic St Georg, Hamburg, GermanyAssmann-Foundation for Prevention, Münster, Germany (creator_code:org_t)

Ingår i:European Journal of Preventive Cardiology: Oxford University Press (OUP)23:3, s. 275-2812047-48732047-4881

Av författaren/redakt...: Müller-Wieland, ...; Assmann, Gerd; Carmena, Rafael; Davignon, Jean; von Eckardstein, ...; Farinaro, Eduard ...; visa fler...; Greten, Heiner; Olsson, Anders G; Riesen, Walter F; Shlyakhto, Evgen ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kardiologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.